Ensysce Biosciences, INC 8-K filings

Ensysce Biosciences has acquired Cy Biopharma, gaining a clinical-stage therapy for CRPS and securing up to $77 million in private financing to advance its pipeline.

Ensysce Biosciences has completed the acquisition of Cy Biopharma, a clinical-stage biotech firm, and secured approximately $43 million in private placement financing to advance a neuroplastogenic therapy for CRPS.

Ensysce Biosciences, Inc. announced the resignation of its Chief Operating Officer, Jeffrey Millard, effective July 10, 2026.

Ensysce Biosciences has received a deficiency notice from Nasdaq for failing to meet the minimum stockholders equity requirement of $2.5 million.

Ensysce Biosciences, Inc. announced the resignation of a Board of Directors member, effective April 1, 2026.

Ensysce Biosciences, Inc. filed a Certificate of Correction to amend a scrivener's error in its Series B Preferred Stock designation related to common stock conversion limits.

Ensysce Biosciences Inc. received a notice from Nasdaq for failing to meet the minimum $1.00 bid price requirement, initiating a 180-day compliance period.

Ensysce Biosciences, Inc. stockholders approved the full issuance of shares and warrants, increased the share pool for its incentive plan, and re-elected two Class I Directors at its annual meeting.

Ensysce Biosciences has closed a $4 million convertible preferred stock financing, with potential for an additional $16 million, to advance its pain management programs.

Ensysce Biosciences reported its third-quarter 2025 financial results, highlighted by the initiation of a pivotal Phase 3 study for PF614 and encouraging FDA feedback for its PF614-MPAR program, alongside a new convertible preferred stock financing.

Ensysce Biosciences initiated a pivotal Phase 3 trial for its lead opioid therapy PF614 and received a $5.3 million NIDA installment, reporting Q2 2025 financial results.

Ensysce Biosciences, Inc. has appointed Baker Tilly US, LLP as its new independent registered public accounting firm following the merger of its previous auditor, Moss Adams LLP, though the prior audit report included an explanatory paragraph regarding a going concern uncertainty.

Ensysce Biosciences announces its Q1 2025 financial results, highlighting progress in clinical trials for opioid abuse and overdose protection, and the receipt of a U.S. patent for its opioid use disorder (OUD) drug candidate, PF9001.

Ensysce Biosciences secures $2.2 million through warrant exercises and a private placement to advance its pain relief programs.

Ensysce Biosciences files a Form 8-K to correct an omission in the consent of its independent registered public accounting firm related to certain registration statements.

Ensysce Biosciences has secured approximately $1.1 million through a registered direct offering and concurrent private placement to fund its TAAP and MPAR programs and for working capital.

Ensysce Biosciences announces its fourth quarter and full year 2024 financial results, highlighting a strategic partnership and positive interim results for its PF614-MPAR trial.

Ensysce Biosciences has entered into a product development and commercial manufacturing agreement with Galephar Pharmaceutical Research, involving up to $10 million in research and development funding in exchange for stock and milestone-based payments.

Ensysce Biosciences has enacted a 1-for-15 reverse stock split, effective December 6, 2024, to consolidate its common stock.

Ensysce Biosciences held its annual meeting on November 21, 2024, where stockholders approved key proposals including a share issuance, a reverse stock split, and the election of three Class III directors.

Ensysce Biosciences announced its third quarter 2024 financial results, highlighted by a $14 million NIH grant and advancements in clinical trials for its pain management therapies.

Ensysce Biosciences has amended its bylaws to lower the quorum requirement for stockholder meetings from a majority to one-third of the total votes, effective November 1, 2024.

Ensysce Biosciences has finalized agreements for a $5 million capital raise through a registered direct offering and the exercise of existing warrants.

Ensysce Biosciences received a delisting notice from Nasdaq due to non-compliance with the $2.5 million stockholders' equity requirement.

Ensysce Biosciences announced progress in its opioid programs, including a Phase 1b study for PF614-MPAR and the selection of PF9001 as a lead drug candidate for opioid use disorder, alongside its second quarter 2024 financial results.

Ensysce Biosciences has regained compliance with Nasdaq's equity requirement, allowing its stock to continue trading on the Nasdaq Capital Market.

Ensysce Biosciences announced its first quarter 2024 financial results and provided updates on its clinical programs, including the planned Phase 3 trial for PF614 and Breakthrough Therapy designation for PF614-MPAR.

Ensysce Biosciences believes it has met Nasdaq's minimum stockholders' equity requirement of $2.5 million following recent warrant exercises.

Ensysce Biosciences has received a notice from Nasdaq for failing to maintain a minimum share price of $1.00, adding to existing concerns about the company's compliance with listing requirements.

Ensysce Biosciences announced its financial results for the fourth quarter and full year 2023, highlighting progress in clinical programs and a Breakthrough Therapy designation for PF614-MPAR.